

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) June 29, 2005

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.  
-----

Maryland  
-----

000-51174  
-----

74-3113410  
-----

525 University Avenue, Suite 700, Palo Alto, CA  
-----

94301  
-----

Registrant's telephone number, including area code 650/289-3060

-----  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

ITEM 8.01 OTHER EVENTS

On July 11, 2005, Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC) announced on June 29, 2005, it entered into an agreement to provide US\$10 million debt financing to the US Subsidiary of Canadian-based Labopharm, Inc. (TSX: DDS).

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1 Press release dated July 11, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

July 11, 2005

/s/ SCOTT HARVEY  
-----

Scott Harvey  
Chief Legal Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION OF EXHIBITS
99.1	Press Release dated July 11, 2005.



HERCULES TECHNOLOGY GROWTH CAPITAL, INC. PROVIDES US\$10 MILLION TO LABOPHARM,  
INC., U.S. SUBSIDIARY

BOSTON, July 11 /PRNewswire-FirstCall/ -- Hercules Technology Growth Capital, Inc. (Nasdaq: HTGC) announces that on June 29, 2005, it entered into an agreement to provide US\$10 million debt financing to the US Subsidiary of Canadian-based Labopharm, Inc. (TSX: DDS). Proceeds from the financing will be used for general corporate purposes, including the commercialization of the Company's once-daily formulation of tramadol in Europe.

"We believe that Labopharm's once-daily formulation of tramadol, combined with their significant drug development pipeline which utilizes their proprietary drug delivery technologies, poises the Company for future success," said Parag Shah, Managing Director, Life Sciences, Hercules Technology Growth Capital.

"This debt financing provides additional capital, with minimal dilution, positioning us to meet several significant milestones in the second half of this year, including the start of sales in Europe of our once-daily tramadol product," stated James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc.

In addition, HTGC has been granted the option to invest up to US\$1 million in Labopharm's next equity financing under the same terms, conditions and pricing offered to participating investors.

About Hercules Technology Growth Capital:

Founded in December, 2003, Hercules Technology Growth Capital, Inc. (Nasdaq: HTGC) is a publicly traded specialized finance company providing debt and equity growth capital to technology-related companies at all stages of development. The Company primarily finances privately-held companies backed by leading venture capital and private equity firms and also may finance certain publicly-traded companies. Hercules focuses its investments in companies active in the technology and technology-related industries. The Company's investments are originated through its principal office located in Silicon Valley, as well as additional offices in the Boston and Chicago areas. Providing capital to privately-held companies backed by leading venture capital and private equity firms involves a certain degree of credit risk and may result in potential losses.

For more information or companies interested in learning more about financing opportunities should contact [info@herculestech.com](mailto:info@herculestech.com) or call at (650) 289-3060 or visit <http://www.herculestech.com>.

About Labopharm Inc.

Labopharm Inc. (TSX: DDS) is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(R), the Company's proprietary advanced controlled-release technology. Labopharm's lead in-house product, a once-daily formulation of the analgesic tramadol, has been approved in France and the Company has initiated the Mutual Recognition Procedure process, which will facilitate regulatory approval across the European Union. In the U.S., the Company's once-daily tramadol product is in pivotal Phase III clinical trials. The Company's pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit <http://www.labopharm.com>.

SOURCE Hercules Technology Growth Capital, Inc.

-0- 07/11/2005

/CONTACT: Scott Harvey, Chief Legal Officer of Hercules Technology Growth Capital, Inc, +1-650-289-3060 /

/Photo: <http://www.newscom.com/cgi-bin/prnh/20050609/SFTH149LOGO/>

/Web site: <http://www.herculestech.com>  
<http://www.labopharm.com>